MARKET

DFTX

DFTX

Definium Therapeutics
NASDAQ
22.01
+0.85
+4.02%
Closed 19:58 05/13 EDT
OPEN
21.19
PREV CLOSE
21.16
HIGH
22.46
LOW
20.83
VOLUME
1.48M
TURNOVER
0
52 WEEK HIGH
26.25
52 WEEK LOW
6.16
MARKET CAP
2.40B
P/E (TTM)
-8.8319
1D
5D
1M
3M
1Y
5Y
1D
Definium Therapeutics (DFTX) Is Down 6.0% After Starting Second Phase 3 DT120 Trial in MDD - Has The Bull Case Changed?
Simply Wall St · 5h ago
Definium Therapeutics: Buy Rating Reiterated with Unchanged $70 Price Target on Robust Late-Stage DT120 Pipeline and De-Risked Phase 3 Programs
TipRanks · 23h ago
Analyst Reiterates Buy on Definium Therapeutics as Late-Stage MDD and GAD Trials Advance; $38 Price Target Maintained
TipRanks · 1d ago
Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (DFTX) and Sagimet Biosciences, Inc. Class A (SGMT)
TipRanks · 1d ago
Definium begins second Phase 3 trial for DT120
TipRanks · 1d ago
Definium Therapeutics says first patient dosed in Ascend study
TipRanks · 1d ago
Definium Therapeutics Dosed First Patient In Ascend Phase 3 Study Of DT120 ODT (Lysergide Tartrate) For Major Depressive Disorder, Topline Data From The 12-week Double-blind Period Is Anticipated In 2027
Benzinga · 1d ago
Definium doses first patient in Phase 3 Ascend trial of DT120 ODT for MDD
PUBT · 1d ago
More
About DFTX
Definium Therapeutics, Inc., formerly Mind Medicine (MindMed) Inc., is engaged in developing therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. The Company plans to advance DT1201 ODT toward FDA submissions in the two largest psychiatric markets, generalized anxiety disorder (GAD) and major depressive disorder (MDD). Its late-stage pipeline includes four Phase 3 trials, two each for GAD and MDD, anchored by its lead candidate, DT120 ODT, which has received an FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is engaged in advancing its commercial strategy and operational readiness to support a care model and prepare for the launch of DT120 ODT, if approved and marketed. It also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).

Webull offers Definium Therapeutics Inc stock information, including NASDAQ: DFTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DFTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DFTX stock methods without spending real money on the virtual paper trading platform.